Lacidipina Teva (Lacidipine)

Lacidipine selectively inhibits L‑type calcium channels on vascular smooth muscle, preventing calcium entry that is necessary for muscle contraction. This inhibition causes vasodilation, decreasing peripheral vascular resistance and ultimately lowering systemic arterial pressure.

The appropriate dose of Lacidipina Teva is determined by the prescribing clinician based on the patient’s blood pressure, response to therapy, and any co‑existing medical conditions. The prescriber will select the strength and dosing schedule that best fits the individual’s needs.

Safety of lacidipine in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacidipine belongs to the dihydropyridine class of calcium channel blockers, offering potent vasodilation with a relatively long half‑life. Compared with other classes such as ACE inhibitors or beta‑blockers, it primarily reduces peripheral resistance and may be preferred when a strong arterial‑relaxing effect is desired.

Lacidipina Teva should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity.

Lacidipina Teva is taken orally, usually once daily, with or without food as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious adverse events, although rare, can include severe hypotension, myocardial infarction, angina, significant liver enzyme elevation, and allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience chest pain, fainting, or signs of an allergic response.

Lacidipina Teva is contraindicated in patients with known hypersensitivity to lacidipine or any component of the formulation, and in individuals with severe aortic stenosis or uncontrolled heart failure. Clinicians should also exercise caution in patients with significant hepatic impairment.